Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Concentrix (CNXC) Shares Outstanding (Weighted Average) (2020 - 2026)

Concentrix's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $61.3 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 4.31% to $61.3 million in Q1 2026 year-over-year; TTM through Feb 2026 was $61.3 million, a 4.31% decrease, with the full-year FY2025 number at $63.0 million, down 3.02% from a year prior.
  • Shares Outstanding (Weighted Average) hit $61.3 million in Q1 2026 for Concentrix, down from $63.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CNXC hit a ceiling of $65.7 million in Q1 2024 and a floor of $51.1 million in Q3 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $58.1 million across 5 years, with a median of $61.3 million in 2026.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 28.38% in 2024 and later dropped 4.31% in 2026.
  • Tracing CNXC's Shares Outstanding (Weighted Average) over 5 years: stood at $51.4 million in 2022, then grew by 4.77% to $53.8 million in 2023, then increased by 20.77% to $65.0 million in 2024, then dropped by 3.02% to $63.0 million in 2025, then dropped by 2.75% to $61.3 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CNXC at $61.3 million in Q1 2026, $63.0 million in Q4 2025, and $62.6 million in Q3 2025.